Menu

Impact Events

More
Date Lead Company Event Type Approval Change Approval Likelihood
4/21/25 Gilead (GILD) Trodelvy for Triple-Negative Breast Cancer (TNBC) Subscribers Only Subscribers Only Subscribers Only
4/17/25 Eli Lilly (LLY) Orforglipron for Diabetes Mellitus, Type II Subscribers Only Subscribers Only Subscribers Only
4/14/25 Bristol (BMY) Camzyos for Cardiomyopathy - Hypertrophic Subscribers Only Subscribers Only Subscribers Only
4/1/25 Alzheon ALZ-801 for Alzheimer's Disease (AD) Subscribers Only Subscribers Only Subscribers Only
4/1/25 Cerevance CVN424 for Parkinson's Disease (PD) Subscribers Only Subscribers Only Subscribers Only

Upcoming Catalysts

More
Expected Date Range Lead Company Drug Expected Catalyst
03/31/2025 Subscribers Only Subscribers Only Trial Announcement - Other
04/01/2025 Subscribers Only Subscribers Only Company - Divestment/Spinoff
04/05/2025 Subscribers Only Subscribers Only Trial Data - Other
04/24/2025 Subscribers Only Subscribers Only Company - Analyst/R&D Update
04/24/2025 Subscribers Only Subscribers Only Trial Data - Updated Results